Jazz Pharmaceuticals CEO Bruce Cozadd's 2020 pay slips 15% to $13M
Jazz Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: 8 minutes ago
Jazz Pharmaceuticals reported fiscal year 2020 executive compensation information on June 11, 2021.
In 2020, five executives at Jazz Pharmaceuticals received on average a compensation package of $5.8M, a 3% increase compared to previous year.
Average pay of disclosed executives at Jazz Pharmaceuticals
Bruce C. Cozadd, Chief Executive Officer, received $13M in total, which decreased by 15% compared to 2019. 47% of Cozadd's compensation, or $5.9M, was in stock awards. Cozadd also received $1.4M in non-equity incentive plan, $4.2M in option awards, $1.1M in salary, as well as $15K in other compensation.
For fiscal year 2020, the median employee pay was $234,935 at Jazz Pharmaceuticals. Therefore, the ratio of Bruce C. Cozadd's pay to the median employee pay was 54 to one.
Kim Sablich, Executive Vice President and General Manager, North America, received a compensation package of $4.6M. 46% of the compensation package, or $2.1M, was in stock awards.
Daniel N. Swisher, Jr, Chief Operating Officer, earned $4.5M in 2020, a 5% decrease compared to previous year.
Renée Gal, Chief Financial Officer, received $4.1M in 2020.
Robert Ianonne, Chief Medical Officer, earned $3.1M in 2020, a 15% decrease compared to previous year.
Related executives
Bruce Cozadd
Jazz Pharmaceuticals
Chief Executive Officer
Daniel Swisher
Jazz Pharmaceuticals
Chief Operating Officer
Renée Gal
Jazz Pharmaceuticals
Chief Financial Officer
Robert Ianonne
Jazz Pharmaceuticals
Chief Medical Officer
Kim Sablich
Jazz Pharmaceuticals
Executive Vice President and General Manager, North America
You may also like
Source: SEC filing on June 11, 2021.